A Novel Sequentially Evolved EML4-ALK Variant 3 G1202R/S1206Y Double Mutation In Cis Confers Resistance to Lorlatinib: A Brief Report and Literature Review

Lorlatinib is a third-generation ALK inhibitor that can overcome the largest number of acquired ALK resistance mutations, including the solvent-front mutation G1202R. Here, we report, for the first time, a novel, sequentially-evolved EML4-ALK variant 3 G1202R/S1206Y double mutation in cis detected i...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhu, Viola W., Nagasaka, Misako, Madison, Russell, Schrock, Alexa B., Cui, Jean, Ou, Sai-Hong Ignatius
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2020
Materias:
Brief Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8474455/
https://www.ncbi.nlm.nih.gov/pubmed/34589977
http://dx.doi.org/10.1016/j.jtocrr.2020.100116

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8474455/
https://www.ncbi.nlm.nih.gov/pubmed/34589977
http://dx.doi.org/10.1016/j.jtocrr.2020.100116

Ejemplares similares